The tankyrase inhibitor G007-LK inhibits small intestine LGR5 stem cell proliferation without altering tissue morphology.

BACKGROUND

The WNT pathway regulates intestinal stem cells and is frequently disrupted in intestinal adenomas. The pathway contains several potential biotargets for interference, including the poly-ADP ribosyltransferase enzymes tankyrase1 and 2. LGR5 is a known WNT pathway target gene and marker of intestinal stem cells. The LGR5 stem cells are located in the crypt base and capable of regenerating all intestinal epithelial cell lineages.

RESULTS

We treated Lgr5-EGFP-Ires-CreERT2;R26R-Confetti mice with the tankyrase inhibitor G007-LK for up to 3 weeks to assess the effect on duodenal stem cell homeostasis and on the integrity of intestinal epithelium. At the administered doses, G007-LK treatment inhibited WNT signalling in LGR5 stem cells and reduced the number and distribution of cells traced from duodenal LGR5 stem cells. However, the gross morphology of the duodenum remained unaltered and G007-LK-treated mice showed no signs of weight loss or any other visible morphological changes. The inhibitory effect on LGR5 stem cell proliferation was reversible.

CONCLUSION

We show that the tankyrase inhibitor G007-LK is well tolerated by the mice, although proliferation of the LGR5 intestinal stem cells was inhibited. Our observations suggest the presence of a tankyrase inhibitor-resistant cell population in the duodenum, able to rescue tissue integrity in the presence of G007-LK-mediated inhibition of the WNT signalling dependent LGR5 intestinal epithelial stem cells.